University of Kentucky

UKnowledge
Sociology Faculty Publications

Sociology

7-16-2021

Longitudinal Pre-Exposure Prophylaxis (PrEP) Acceptability,
Initiation and Adherence among Criminal Justice-Involved Adults
in the USA: The Southern PrEP Cohort Study (SPECS) Protocol
Katherine LeMasters
University of North Carolina at Chapel Hill

Carrie B. Oser
University of Kentucky, carrie.oser@uky.edu

Mariah Cowell
University of North Carolina at Chapel Hill

Katie Mollan
University of North Carolina at Chapel Hill

Kathryn Nowotny
University of Miami
Follow this and additional works at: https://uknowledge.uky.edu/sociology_facpub
Part of the Epidemiology Commons, Inequality and Stratification Commons, Social Work Commons,
See next page for additional authors
and the Substance Abuse and Addiction Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Repository Citation
LeMasters, Katherine; Oser, Carrie B.; Cowell, Mariah; Mollan, Katie; Nowotny, Kathryn; and BrinkleyRubinstein, Lauren, "Longitudinal Pre-Exposure Prophylaxis (PrEP) Acceptability, Initiation and Adherence
among Criminal Justice-Involved Adults in the USA: The Southern PrEP Cohort Study (SPECS) Protocol"
(2021). Sociology Faculty Publications. 24.
https://uknowledge.uky.edu/sociology_facpub/24

This Article is brought to you for free and open access by the Sociology at UKnowledge. It has been accepted for
inclusion in Sociology Faculty Publications by an authorized administrator of UKnowledge. For more information,
please contact UKnowledge@lsv.uky.edu.

Longitudinal Pre-Exposure Prophylaxis (PrEP) Acceptability, Initiation and
Adherence among Criminal Justice-Involved Adults in the USA: The Southern
PrEP Cohort Study (SPECS) Protocol
Digital Object Identifier (DOI)
https://doi.org/10.1136/bmjopen-2020-047340

Notes/Citation Information
Published in BMJ Open, v. 11, issue 7, e047340.
© Author(s) (or their employer(s)) 2021
This is an open access article distributed in accordance with the Creative Commons Attribution Non
Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work
non-commercially, and license their derivative works on different terms, provided the original work is
properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial.
See: https://creativecommons.org/licenses/by-nc/4.0/.

Authors
Katherine LeMasters, Carrie B. Oser, Mariah Cowell, Katie Mollan, Kathryn Nowotny, and Lauren BrinkleyRubinstein

This article is available at UKnowledge: https://uknowledge.uky.edu/sociology_facpub/24

Protocol

Longitudinal pre-exposure prophylaxis
(PrEP) acceptability, initiation and
adherence among criminal justice-
involved adults in the USA: the
Southern PrEP Cohort Study
(SPECS) protocol
Katherine LeMasters  ,1,2 Carrie Oser,3 Mariah Cowell,2,4 Katie Mollan,1,5
Kathryn Nowotny,6 Lauren Brinkley-Rubinstein2

To cite: LeMasters K, Oser C,
Cowell M, et al. Longitudinal
pre-exposure prophylaxis
(PrEP) acceptability, initiation
and adherence among
criminal justice-involved
adults in the USA: the
Southern PrEP Cohort Study
(SPECS) protocol. BMJ Open
2021;11:e047340. doi:10.1136/
bmjopen-2020-047340
►► Prepublication history for
this paper is available online.
To view these files, please visit
the journal online (http://dx.doi.
org/10.1136/bmjopen-2020-
047340).

Received 25 November 2020
Accepted 07 July 2021

© Author(s) (or their
employer(s)) 2021. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published by
BMJ.
For numbered affiliations see
end of article.
Correspondence to
Katherine LeMasters;
katherine.lemasters@unc.edu

ABSTRACT
Introduction HIV prevalence among criminal justice
(CJ)-involved adults is five times higher than the general
population. Following incarceration, CJ-involved individuals
experience multilevel barriers to HIV prevention. Pre-
exposure prophylaxis (PrEP) is a widely available, daily
medication efficacious in preventing HIV. Little is known
about PrEP knowledge, acceptability, initiation and
sustained use among CJ-involved persons or about how
these outcomes vary by multilevel factors. The Southern
Pre-Exposure Prophylaxis Study (SPECS) will investigate
barriers and facilitators for PrEP initiation and sustained
use among CJ-involved adults, building a foundation for
PrEP interventions for this underserved population.
Methods and analysis SPECS uses a mixed-methods
sequential design, including a multisite, prospective cohort
study in three southern states—North Carolina, Florida
and Kentucky—and subsequent qualitative interviews.
HIV-negative adults clinically indicated for PrEP with CJ-
involvement in the past year (n=660; 220 per site)—will
be recruited for four quantitative interviews separated
by 6 months, with 18 months of follow-up. Interviews
will measure CJ involvement, substance use, sexual
behaviours, PrEP acceptability and use, healthcare access
and utilisation, support systems and psychological and
emotional well-being. We will estimate probabilities of
PrEP acceptability and use in a CJ-involved population
using descriptive and multivariable analyses. After the
follow-up, a subsample that never initiated PrEP, initiated
but did not sustain PrEP or sustained PrEP will be asked
to participate in a qualitative interview to contextualise
their experiences and decisions around PrEP. An inductive
approach will guide qualitative analyses.
Ethics and dissemination PrEP initiation and sustained
use rates are unknown among CJ-involved adults. This
research will identify individual, social and structural
factors that predict PrEP initiation and use. Data generated
from the study have the potential to guide research and
the development and tailoring of PrEP interventions to
CJ-involved populations and provide context to HIV-related
outcomes for those with CJ experiences.

Strengths and limitations of this study
►► This is the first pre-
exposure prophylaxis (PrEP)-

related multisite, observational cohort among a
criminal justice (CJ)-involved population, which is
important as rates of PrEP initiation and sustained
use remain unknown among those with recent CJ
experience.
►► This study will collect longitudinal data relevant to
the individual, social and structural level for CJ-
involved populations and will include HIV risk profiles typically excluded from studies on CJ-involved
populations, including men who have sex with men.
►► We are focused on populations in the southern USA,
which sit at the intersection of a number of HIV risk
factors and have received less attention than other
regions of the USA.
►► We are relying primarily on self-reported PrEP initiation and sustained use, which are susceptible to
recall bias.
►► It is possible that few participants will initiate or sustain PrEP.

INTRODUCTION
In the USA, 1 in every 38 adults is actively
involved in the criminal justice (CJ) system.1
Of the 6.6 million CJ-
involved adults, over
two-thirds or 4.5 million, are under a form
of community-
based supervision such as
probation or parole.1 While incarceration
rates for white Americans is increasing, the
CJ system continues to disproportionally
affect persons of colour (POC). In particular,
black and Latinx adults are significantly over-
represented in incarcerated populations.
Although they represent 12% and 16% of
the adult population in the USA, respectively,
black and Latinx Americans make up 33%
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and 23% of the adult prison population.2 3 Racial disparities in incarceration rates are stark among young black
men aged 18–19, who are 12 times more likely to experience incarceration than their white peers.3
Vulnerable populations, such as those experiencing
poverty, homelessness, severe and persistent mental illness
or substance use disorders, are frequently trapped by the
revolving doors of the CJ system and experience multiple
periods of incarceration in their lifetime.4–6 Increasingly,
as a consequence of the opioid epidemic, there is a strong
relationship between the intensity of opioid use and
history of CJ involvement among people who inject drugs
(PWIDs).7 Therefore, it is unsurprising that the American
South, which sees a confluence of racial discrimination,
poverty and disenfranchisement, has incarceration rates
among the highest in the nation.8–10 Notably, we also see
the disparities in mass incarceration reflected in risks of
HIV transmission. There is a high concentration of those
with—or at risk of—HIV infection concentrated in the
US correctional system.
HIV prevalence among CJ-involved adults is five times
that of the general population, and an estimated one in
seven individuals infected with HIV pass through the CJ
system each year.11 12 While incarcerated, CJ-involved individuals are at risk of coming in contact with HIV through
unsterile needle practices, tattooing and condomless sex.
Following periods of incarceration, individuals may also
rapidly re-engage with risky behaviour that increases the
risk of transmission, including injection drug use and
condomless sex, making periods following incarceration
high risk for community-based HIV transmission.13–15 In
the American South, where, like incarceration, HIV prevalence is among the highest in the USA, black Americans
account for 54% of new HIV diagnoses.16 It is clear that
the collateral effects of incarceration on HIV risk among
POC, including creating and perpetuating imbalanced
gender ratios in communities due to the disproportionate incarceration of Black men and thus facilitating
partnership concurrency, and disrupting access to healthcare, contribute to disproportionally high rates of HIV
among this population.11 14 17–19 As identified in a 2016
report from the Centers for Disease Control and Prevention (CDC), the South’s high rates of opioid use, HIV
stigma, poverty levels, and poor healthcare infrastructure
have created a perfect storm for an HIV outbreak.16 In
particular, HIV stigma in the South around sexual orientation, substance use, poverty and sex work limits people
disclosing their HIV status, adhering to antiretroviral
medications and seeking healthcare.9 20 Despite this, HIV
prevention efforts thus far, including interventions to link
people to HIV care postrelease and risk reduction interventions, have led to little meaningful change in reducing
rates of infection in CJ-involved persons in the South.
The failure of traditional approaches (eg, promoting
HIV testing and the use of condoms) to address
expanding risk of HIV infections among people most at
risk has led to new HIV prevention strategies that combine
behavioural and biomedical approaches. In addition to
2

early diagnosis and sustained treatment of HIV infection,
daily preventative treatment—pre-exposure prophylaxis
(PrEP) emtricitabine/tenofovir (FTC/TDF)—has been
credited with recent reductions in rates of new HIV diagnoses in the USA.21 Efficacy of PrEP has been established
in randomised control trials and open label studies and
is approved by the FDA for HIV prevention.22 23 PrEP has
been recommended by the CDC for any at-risk population, including men who have sex with men (MSM),
PWIDs and heterosexuals who engage in condomless sex
with at risk populations. The PrEP care cascade includes
identifying those at highest risk for HIV, increasing HIV
and PrEP awareness among those individuals, initiating
PrEP, and retaining individuals in PrEP care.24
Despite its efficacy, PrEP uptake has been slow. It is
estimated that 1.1 million Americans are candidates for
PrEP—those engaging in high risk sex or unsafe injection
drug use—yet, current reports indicate that as few as 7%
of PrEP candidates have been prescribed PrEP.25 26 Little
is known about PrEP use among those on post-release
supervision/parole and probation, and challenges to
PrEP use among these populations is abundant. To be
most efficacious, oral PrEP must be taken daily. Additionally, as a prescribed medication, PrEP must be offered to
candidates in a clinical setting, followed by regular monitoring for adverse effects, sustained use and sexually transmitted infections (STIs) including HIV. Procurement of
PrEP also requires navigating systems to cover the cost of
the medication and attendant testing. A major additional
challenge is an under appreciation of HIV acquisition risk
among those who the WHO consider to be at substantive
risk. Substantive risk is defined as individuals belonging
to a group that has a disproportionate burden of HIV,
which includes CJ populations.27 Therefore, despite its
promise, PrEP is underutilised and understudied in one
of the most at-risk populations in the US—individuals
with recent CJ involvement.
Objectives
Exposure
This paper describes The Southern Pre-
Prophylaxis Study (SPECS), which uses a mixed-methods
sequential design. SPEC includes a prospective observational cohort study, followed by qualitative interviews
which are designed to respond to and close the knowledge gap regarding PrEP and those involved in the CJ
system. SPECS is a multisite, 5-year study that will take
place in three, diverse southern settings: North Carolina,
Kentucky, and Florida. The specific aims of this study
are to: (1) characterise PrEP knowledge and acceptability among those placed on postrelease supervision/
parole or probation within the last 12 months, (2) identify the multilevel factors that predict PrEP initiation and
sustained use among those placed on post-release supervision/parole or probation within the last 12 months and
(3) qualitatively assess the multilevel factors that affect
PrEP acceptability, initiation and sustained use to inform
future intervention development.
LeMasters K, et al. BMJ Open 2021;11:e047340. doi:10.1136/bmjopen-2020-047340
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will be at substantial risk for HIV infection based on CDC/
WHO criteria for PrEP eligibility: PWIDs, persons with
recent bacterial STI diagnosis, and/or individuals who
are at a higher risk for being exposed to HIV through sex,
including MSM and those with infrequent condom use.

Figure 1 The social ecological model of PreP use. CJ,
criminal justice; PrEP, pre-exposure prophylaxis.

Broad goals for the study
The significance of the study is punctuated by the
confluence of the continuing dual epidemics of incarceration and HIV. Very few studies have examined knowledge, acceptability, initiation and sustained use of PrEP
among individuals with CJ involvement. Importantly,
the proposed investigations will identify the multilevel
barriers and facilitators that predict PrEP initiation and
sustained use among parolees and probationers, building
the foundation for next-step PrEP interventions for this
largely underserved population.
Conceptual framework
Both the socioecological model and the National Institute of Minority Health and Health Disparpities research
framework inform SPECS,28 29 centralising the importance of health disparities that span multilevel domains of
influence. Specifically, these domains extend beyond the
individual to consider the importance of social and structural factors and their responsibility for reducing health
inequalities.28 29 These frameworks will be used in combination to observe and study the longitudinal patterns
of PrEP initiation and sustained use among people on
probation and parole, who are disproproportionately
POC and experience health disparities (figure 1).
METHODS AND ANALYSES
Study design
This study is a prospective longitudinal cohort of individuals with CJ involvement and a clinical indication for
PrEP in North Carolina, Florida and Kentucky.
Participants
Participants will be HIV negative adults over the age of
18 who were placed on postrelease supervision/parole or
probation within the last 12 months. Eligible participants
LeMasters K, et al. BMJ Open 2021;11:e047340. doi:10.1136/bmjopen-2020-047340

Recruitment
Participants will be recruited at three study sites with the
following enrolment goals: NC (n=220), KY (n=220) and
FL (n=220). Recruitment will occur at local probation
and parole offices in Durham and Raleigh, NC, Miami, FL
and Lexington, KY. Study team members will approach
individuals in the waiting room at each local probation
and parole office, and screen in a private on-site room.
Participants will provide written informed consent. Participants may understandably feel uncomfortable answering
questions about sensitive subjects like sexual activity and
substance use while at a probation and parole office. They
will be provided with the option of completing prescreen
surveys over the phone or at an off-site venue, such as the
university or study community office.
Quantitative data collection
Standard study assessments will be conducted at baseline, 6 months, 12 months and 18 months, using Research
Electronic Data Capture programmed surveys. At all
timepoints, participants will answer questions related
to the three domains in the social ecological model of
PrEP use,25 26 including items on individual level factors
(ie, sociodemographic information; CJ involvement;
substance use; sexual risk behaviour; PrEP acceptability,
initiation, and sustained use; medical comorbidities;
healthcare utilisation), social level factors (eg, stigma and
discrimination; social support30 31) and structural level
factors (healthcare access; housing access; employment;
public transportation). Participants will also be tested for
HIV at baseline and at the end of the study at 18-month
follow-up with an OraQUICK ADVANCE Rapid HIV-1/2
test. When HIV tests are administered at baseline and
18 months, participants will also receive pretest, post-
test and PrEP counselling. All participants that receive a
positive HIV test will receive support to access HIV care;
however, those that receive a positive HIV test at baseline
are ineligible for study enrolment. At baseline, participants will complete a locator form for which information
will be updated during phone calls at 3 months, 9 months
and 15 months. This form contains contact information
for the participant (eg, phone numbers, address, social
media handles) as well as for key family or friends. Participants will receive US$40 per interview and US$10 per
phone call. Participants completing all interviews and
phone calls will receive US$190.
Retention and attrition
We recognise that CJ-involved populations are difficult
to retain in longitudinal studies (ie, due to recidivism,
substance use, unstable housing), but our research team
has been successful in limiting study attrition among
3
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CJ-involved populations.32 33 Therefore, we postulate that
we will be able to retain 80% of our study population for
18-month follow-up.
This study will employ multiple processes to support
participant retention over 18 months of data collection.
These strategies operate at both the individual and
organisational level. At the individual level, we will do
same-
day screening, enrolment and assessment when
possible. Every 3 months, we will check-in with participants by phone, email, and field contact and will subsequently update locater information forms and send
letters and postcards. Throughout the study, we will
send personalised notes to participants (ie, birthdays,
holidays), schedule appointments outside of their work
hours and in the community that is most convenient for
them, provide monetary incentives, establish a study Facebook page, and conduct active case-finding for persons
lost to follow-up (ie, internet searches, home visits). At
the organisational level, we will develop a study logo and
branding, conduct weekly automated prison and jail database searches, and have regular team conference calls. At
year one, we will have a retention training workshop and
conduct study and site training.
Each site will tailor or add additional methods based
on experience and resources and sites will continually
communicate with each other to ensure adherence to
all retention methods. Additionally, through engaging in
automated prison and jail database searches, we will track
participants in real time as they experience incident reincarceration. Individuals that become reincarcerated will
remain in the study if they are able to attend scheduled
study visits after incarceration.
Study exposures and outcomes
Our outcomes for aim 1 are PrEP knowledge and acceptability. PrEP knowledge will be assessed by asking participants if they have prior knowledge of PrEP and PrEP
acceptability will be assessed using the Willingness to Use
PrEP scale.34 35 Our outcomes for aim 2 are PrEP initiation and sustained use. PrEP initiation is a dichotomous
measure defined as receiving/filling a prescription for
PrEP as reported at the first follow-
up assessment (at
6 months). Sustained use is defined as self-report daily
adherence assessed by the number of PrEP doses taken

in the last 30 days. This measure of adherence will be
collected at 6, 12 and 18 months follow-ups. Self-reported
adherence will be supplemented by clinical chart abstraction. Secondary outcomes for aim 2 are HIV seroconversion (~20 seroconversions are anticipated) as well as
dichotomous and count measures of non-PrEP-related
health service utilisation (eg, emergency department,
other preventative care) and behaviours associated with
high HIV risk. A combination of individual (eg, healthcare utilisation), social (eg, social support) and structural
factors (eg, re-incarceration) serve as exposure variables
of interest.
The study is using a sequential design in which aim 3
builds on aims 1 and 2 to help elucidate patterns of PrEP
use and multilevel factors that facilitate or act as barriers
to PrEP knowledge, initiation, and sustained use. Specifically, aim 3 includes qualitative interviews which are
designed to illicit a rich descriptive narrative regarding
the PrEP continuum of care. Example questions include
‘Describe how concerned you are that other people know
you are on (or might be considering) PrEP?” or “If we
were going to create an intervention that would help
support you in getting your PrEP prescriptions, getting to
the clinic, and taking PrEP every day, what do you think
would be helpful?’
Sample size calculations
Retention of participants is assumed to be 80% at each
follow-up through 18 months (ie, 528 evaluable at each
follow-up). A primary objective of Aims 1 and 2 is to
estimate the probabilities of PrEP knowledge, acceptability, initiation and sustained use, overall and at each
site. The anticipated proportions having these outcomes
are unknown. Table 1 provides precision calculations for
observed proportions ranging from 50% to 90%. Power
to detect associations depends on the true probabilities
of PrEP knowledge, acceptability, initiation and sustained
use is shown in table 2.
For example, analysing the full cohort and a covariate
with 50% prevalence, there will be sufficient power
(>80%) to detect an OR of 2.0 or larger at a single time
point for a reference group proportion (P) with the
outcome event (eg, PrEP initiation) ranging from 20%
to 80% (table 2 presents P: 50%–80%). For site-specific

Table 1 Precision calculations for proportions with PreP knowledge, acceptability and initiation
Full cohort (528 evaluable)

Site-specific (176 evaluable)

Proportion (95% CI)

CI half-width

Proportion (95% CI)

CI half-width

0.5 (0.46 to 0.54)
0.6 (0.56 to 0.64)

0.043
0.043

0.5 (0.42 to 0.58)
0.6 (0.53 to 0.68)

0.076
0.075

0.7 (0.66 to 0.74)

0.040

0.7 (0.63 to 0.77)

0.070

0.8 (0.76 to 0.83)
0.9 (0.87 to 0.92)

0.035
0.027

0.8 (0.73 to 0.86)
0.9 (0.84 to 0.94)

0.061
0.048

Exact binomial 95% CIs are shown.
PrEP, pre-exposure prophylaxis.
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Table 2 Power to detect association between an
independent variable with 50% prevalence and PrEP
outcomes (N=528 evaluable)
OR

P=0.5

P=0.6

P=0.7

P=0.8

1.75
2.00
2.25

88.7
97.3
99.5

85.6
95.8
98.9

78.6
91.7
97

65.0
80.9
90.0

p=proportion with the outcome (eg, PrEP initiation) in the reference
group.
PrEP, pre-exposure prophylaxis.

analyses, an OR of 3.5 or larger at a given time point will
be detectible with >85% power for P ranging from 10% to
70%. Longitudinal analyses incorporating measurements
from baseline, 6, 12, and 18 months will have higher
power that will be impacted by within-individual correlations over time. Analyses of sustained PrEP use will be
among the subsample who initiate PrEP and site-specific
analyses of sustained PrEP will be descriptive.
Qualitative data collection
SPECS cohort participants will be categorised into the
following three groups for each site: never initiated PrEP,
initiated but did not sustain and initiated and sustained.
Research randomiser (www.randomizer.org) will be used
to randomly select eight or nine individuals from each
of the three groups to participate in the qualitative interview. Enrollment will continue until data analysis reflects
saturation, with 25 interviews anticipated at each study
site and approximately an equal number of interviews of
parolees who (1) never initiated PrEP, (2) initiated PrEP
but did not sustain use and (3) initiated and sustained use
of PrEP. Participants will receive US$40 for completing
the interview. Interviews will take place in year 4 and 5
so the qualitative sample will include those who had long
term, sustained use of PrEP. In-depth qualitative interviews will last 60–90 min and will take place face-to-face,
in a private room at a community-based venue convenient
for the participant. All interviews will be digitally recorded
and professionally transcribed. Team members who have
training and expertise in qualitative research will conduct
the interviews. Content of interviews will be guided by the
conceptual framework, our research objectives, and findings from the quantitative data collected via aims 1 and 2.
However, we expect to explore the domains below:
1. Risk compensation. Example questions will include:
(1) Has your HIV risk behaviour changed over time,
recently, please explain? For instance, is there a period
in the past when you were engaging in risky behaviour
and then a time when you thought you definitely were
not? Can you tell me about those times? (2) Do you
think use of PrEP affected your risk engagement, why/
why not?
2. Knowledge, acceptability and experience related to
PrEP initiation/sustained use. Example questions will
include: (1) Can you tell me a little bit about your exLeMasters K, et al. BMJ Open 2021;11:e047340. doi:10.1136/bmjopen-2020-047340

perience with PrEP (prompts for follow-up will include
questions relevant to the PrEP clinic and provider,
their experience accessing PrEP clinic visits and availability of PrEP in their community, etc); (2) When you
think about making the decision to stay on PrEP or
not take PrEP, what comes to mind as something that
helped you make that decision?
3. The multilevel barriers/facilitators of PrEP initiation/
sustained use and suggestions for future PrEP intervention components. Example questions will include: (1)
Earlier I asked if anything you had been dealing with
might be affecting your HIV risk behaviour, similarly,
do you think any of the things you’ve been dealing
with might have affected your PrEP use, why/why not?;
(2) Were you ever concerned what other people would
think if they knew you were on (or might be considering) PrEP? (3) If we were going to create an intervention that would help support you in getting your PrEP
prescriptions, getting to the clinic, and taking PrEP every day, what do you think would be helpful?
4. Interest in new PrEP modalities. Example questions
will include: (1) There are many different emerging
models for how to get PrEP. Would you be interested in
getting PrEP from a shot that you only had to get every
few months, why/why not? (2) Would you be interested in getting your PrEP prescription in the mail, why/
why not? (3) Would you be interested in completing a
self-HIV test at home every 3 months and mailing it to
the clinic instead of having to have an in person visit,
why/why not? (4) Which of these options would you
most prefer?
Quantitative analyses
Data analysis will be guided by our conceptual framework,
which postulates that PrEP knowledge, acceptability,
initiation and sustained use are impacted by multilevel
factors at the individual, social and structural levels. The
multilevel nature of these factors will be considered when
constructing analytic models. Quantitative analyses will
be conducted using the full cohort of 660 participants
and also evaluated within each site (n=220 per site) to
elucidate state-specific outcomes. Both aims 1 and 2 will
use a descriptive, bivariate and multivariable approach
for analyses. Aim 1 multivariable analyses will use (1)
generalised linear models (GLM) to estimate associations between independent variables (ie, exposures) and
the outcomes of (A) PrEP knowledge and (b) average/
high PrEP acceptability. We will estimate model-
based
predicted probabilities of PrEP acceptability based on
key independent variables (eg, sex, race/ethnicity, sexual
identity, CJ history, MSM, IDU) to elucidate key subpopulations where future interventions are needed to improve
PrEP acceptability. Aim 2 will conduct multivariable analyses using GLMs to analyse longitudinal data for sustained
PrEP use, and will examine results at each follow-up time
point. Generalised estimating equations with robust SE
estimates36 37 will be used to estimate parameters of a
GLM; a priori we will assume an exchangeable working
5
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correlation structure. Covariate associations with PrEP
initiation, time-to-initiation and number of PrEP clinic
appointments kept will also be analysed. We will estimate associations between individual, social, and structural factors and time to initiation of PrEP, with proper
handling of right-censored observations for those who do
not initiate PrEP.38 39 While our primary outcome of PrEP
initiation will be measured at 6-month follow-up, PrEP
initiation can be examined at all follow-up time points.
Additional secondary outcomes of interest include: HIV
seroconversion (~20 seroconversions are anticipated),
non-PrEP-related health service utilisation, reincarceration and substance use. Missing data will be an important
consideration, and will be handled in multivariable
analyses using a missing at random assumption, when
deemed tenable, via application of multiple imputation
or inverse probability of missingness weights.40–42 If data
are suspected to be missing not at random, this will be
described as a limitation.
Qualitative analyses
Aim 3 will qualitatively assess the multi-level factors that
affect PrEP acceptability, initiation and sustained use
to inform future intervention development. A general
inductive approach guided by the conceptual framework
and the research objectives will be used.43 A preliminary
codebook will be developed after the first three transcripts
from each category (eg, those who never started PrEP,
those who initiated but did not sustain PrEP use, and
those who sustained PrEP use) are complete. The coding
scheme will be tested and two coders will code the text
segments, compare coding and discuss and resolve areas
of discrepancy, and then code another 20 text segments
and percentage agreement will be calculated. Open
coding will be done first followed by broad thematic analysis. Transcripts will be coded with axial codes, or more
interpretive codes, that will be used in order to identify
core concepts. In addition, memos and theory notes will
be generated throughout the analysis.
Timeline
During the Fall of 2019, we will begin cohort recruitment
and follow-up, which will continue through the Summer
of 2022. Aim 1 analysis will take place in 2021–2022
while aim 2 analysis will take place in 2021–2023. Aim 3
protocol development and recruitment will take place in
the second half of 2021 while aim 3 data collection and
analysis will take place in 2022–2023. Dissemination of
findings will take place in 2021–2023.
Patient and public involvement
No patients involved.
The coronavirus pandemic
Due to the coronavirus pandemic, we will adjust our
recruitment and retention efforts. In March of 2020,
in-person recruitment and retention will pause and transition to conduct all retention virtually through phone
calls. For retention, we will send personalised mailers
6

to enrolled participants, pay participants for contacting
SPECS’ staff, and give participants a bonus for completing
their retention visits within a week of when they were
scheduled. We will also begin a coronavirus survey with an
additional cash incentive for enrolled participants. With
additional incentives, particpants will go from earning
up to US$190 to earning up to US$265 for completing
SPECS.
Recruitment will be paused beginning March 2020.
When feasible, we will resume recruitment using chain
referral, asking enrolled participants to refer up to five
potentially eligible peers to us (ie, anyone placed on
probation, postrelease supervision or parole in the past
12 months). Enrolled participants will receive US$10 for
each referral, regardless of if the referalls qualify for the
study. Qualifying individuals will complete the baseline
interview over the phone. Once it is safe to do so, we will
return to in-person recruitment and retention.

ETHICS AND DISSEMINATION
While PrEP is highly effective at preventing HIV, it will
be most effective if used by those for whom traditional
approaches for HIV prevention have failed. HIV prevalence among CJ-involved populations remains five times
that of the general population, yet little remains known
about PrEP uptake among CJ-involved individuals and
about facilitators and challenges to PrEP uptake and
sustained use.12 By adopting a conceptual framework that
recognises PrEP decisions are made within individual,
social and structural levels, SPECS is designed to respond
to and close the knowledge gap regarding PrEP among
people involved in the CJ system.
The SPECS cohort will establish a platform to support
future research related to PrEP outcomes among
parolees. We suspect that future research could include:
(1) Comparison of PrEP-related outcomes among cohort
members who do and do not become re-incarcerated
during the study period; (2) Spatial epidemiological
analyses using geographic information derived from
offender databases and collected from cohort participants and (3) Study of the possible effect of Medicaid
expansion in KY and non-expansion of Medicaid in FL
and NC. Similarly, we can compare across states for other
outcomes. In terms of future interventions, we anticipate
the results of SPECS will highlight specific needs that
should be addressed for certain subgroups. For example,
our results could indicate that some subgroups might
be more likely to initiate PrEP but less likely to engage
in sustained use—identifying a key intervention time
point in the PrEP care cascade. We could also find that
certain groups experience very specific barriers to PrEP
use postrelease, identifying the need to provide tailored
support. Therefore, SPECS will lay the groundwork for
future randomised clinical trials to evaluate the efficacy
of multiple PrEP-related interventions that are tailored
for CJ-involved individuals.
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Ethical concerns
A primary ethical concern is that we are collecting highly
sensitive, personal information from a population that
often experiences stigma and discrimination and is at high
risk for recidivism. Specifically, we collect information on
activities that are illegal, notably illicit drug use. Recognising this, the collection of identifiable information will
be minimised to the greatest extent possible. Extensive
efforts will be dedicated to protecting the confidentiality
and privacy of study participants. Specifically, all data will
be stored in a deidentified format and only accessed by
the study team. Participants will be thoroughly briefed
on these protections as part of the consent process. The
study’s protocol and procedures have been reviewed
and approved by the institutional review boards at the
University of North Carolina at Chapel Hill (18–2466).
In addition, participants are protected under a federal
Certificate of Confidentiality.
Additionally, the baseline assessment may take place
in private rooms in probation and parole offices, or a
community venue of the participant’s choice (eg, private
room at the university or a community-
based organisation). The baseline assessment at the probation and
parole office is often ideal, as we can recruit from the
waiting room and each site has been given a private space
to screen and conduct the baseline assessment. However,
we acknowledge that it will be important to reassure
participants, during the consent procedure that their
answers will be confidential, and issues discussed will in
no way impact their CJ status, nor ability to obtain or be
referred to medical care or social services. In addition,
we will not share the purpose of the study with individual
probation or parole officers. Instead, this study will be
referred to broadly as a ‘health study’.
Methodological limits and concerns
This study has methodological limitations that merit
further discussion. First, it is possible that we will not
recruit the number of participants needed at each site.
If this is the case, we will expand recruitment to additional district offices in each site location. In addition,
if needed, we will expand to recruit from community-
based organisations. Similarly, it is possible that we retain
fewer than 80% of participants. If this is the case, we will
redirect the duties of one research staff member at each
site to focus solely on retention efforts. If retention is
below 80%, we will also increase the dollar amount of the
follow-up incentives. Second, while we assume a sizeable
portion of our cohort will initiate and sustain PrEP, the
proportion may be low. As a part of our power calculations, we have estimated a wide range of possible outcome
events. Therefore, even if the number of individuals who
initiate and sustain PrEP is low, we should have the power
to perform our planned analyses. In addition, if we find
that few people initiate and sustain PrEP, we will reorient
aim 3 to focus on the reasons for non-initiation or unsustained use. Third, while the most robust PrEP adherence
measure would be to measure drug concentration in dried
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blood spots (DBS), this is very expensive and typically not
world PrEP observational studies. We
feasible for real-
are, therefore, assessing adherence using self-reported
number of missed doses in the past 30 days. Recall over
30-day periods is commonly used as a measure of adherence, and these measures have demonstrated reliability
when compared with objective measures of adherence. In
addition, this adherence measure has been found to be
highly consistent with drug concentrations found using
DBS analysis of PrEP.44 Lastly, cohort studies may bias,
due to recall and social desirability bias of self-reported
measures, in-
selection bias due to HIV-
related stigma,
out-selection bias due to attrition, and data missing not
at random.

CONCLUSIONS
There are many reasons to study the health of CJ-involved
populations in the US South, specific to and beyond HIV
prevention. The CJ system and HIV continue to disproportionally affect POC and vulnerable populations, and
these effects are strongest in the US South. While SPECS
aims to contribute to the growing body of literature on
PrEP uptake and retention among this population, it
also aims to address inequities in research, specifically
the paucity of data that can be used to improve the lives
and health of CJ-
involved populations at risk of HIV.
This study’s dataset will provide the potential to answer
related questions to reduce the risk of HIV and ultimately
improve the lives of these individuals.
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